SCHEMBL2861085

SCHEMBL2861085

Cc1ccc(Oc2ccc(-n3nc4c(c3N)c(=O)[nH]c3cc(OCCCN5CCOCC5)ccc34)cc2)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.42
FGFR1 P11362 2/20 0.42
PDGFRB P09619 1/20 0.42
KDR P35968 1/20 0.42
FGFR2 P21802 1/20 0.41
FGFR3 P22607 1/20 0.41
KDM4E B2RXH2 3/20 0.41
JAK2 O60674 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CSF1R P07333 1/20 0.38
SIGMAR1 Q99720 2/20 0.38
DHODH Q02127 1/20 0.37
RAF1 P04049 1/20 0.37
MAP2K1 Q02750 1/20 0.37
HRH3 Q9Y5N1 2/20 0.37
MET P08581 1/20 0.37
PARP1 P09874 1/20 0.37
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857971 0.90 FGFR1 (0.48) MAOAFGFR1PDGFRBKDRKDM4E
SCHEMBL2861337 0.89 KDM4E (0.50) MAOAFGFR1PDGFRBKDRFGFR2
SCHEMBL2865177 0.87 FGFR1 (0.45) MAOAFGFR1PDGFRBKDRFGFR2
SCHEMBL2867604 0.86 FGFR1 (0.43) MAOAFGFR1PDGFRBKDRFGFR2
SCHEMBL2861595 0.84 FGFR1 (0.43) MAOAFGFR1PDGFRBKDRFGFR2
SCHEMBL2864303 0.84 FGFR1 (0.48) FGFR1PDGFRBKDRKDM4EHSD17B10
SCHEMBL2866809 0.84 MCHR1 (0.51) FGFR1PDGFRBKDRKDM4EHTT
SCHEMBL2866686 0.83 CSF1R (0.45) MAOAFGFR1PDGFRBKDRKDM4E
SCHEMBL2870417 0.83 PDGFRB (0.43) MAOAFGFR1PDGFRBKDRKDM4E
SCHEMBL2865355 0.82 FGFR1 (0.43) MAOAFGFR1PDGFRBKDRFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 MAOA 2993/4885FGFR1 201/4885PDGFRB 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.